Novo Nordisk adjusts strategy in India to compete with generic drugs

Novo Nordisk adjusts strategy in India to compete with generic drugs

In a major shift for the Indian pharmaceutical landscape, Novo Nordisk has significantly reduced the prices of its blockbuster drugs, Ozempic and Wegovy.

orgNovo Nordisk
techOzempic
techWegovy

Following the April 2026 patent expiry for semaglutide, the company faced stiff competition from local manufacturers like Sun Pharma and Dr.

techsemaglutide
orgSun Pharma

Reddy’s.

To stay relevant, Novo Nordisk lowered its starting dose prices by 36% for Ozempic and 48% for Wegovy.

orgNovo Nordisk
techOzempic
techWegovy

With India’s GLP-1 market expected to reach Rs 5,000 crore by 2030, this price adjustment is designed to broaden patient access and secure a dominant position in a price-sensitive market.

locationIndia
techGLP-1

By positioning itself as a reliable, quality-focused provider, Novo Nordisk hopes to navigate the evolving competition while maintaining its premium status among healthcare professionals and patients alike.

orgNovo Nordisk
🎉

End of article

You read 6 focus sentences.

Challenge Mode

Comprehension Questions

Why did Novo Nordisk decide to reduce prices in India?

✓

Correct Choice

To remain competitive against new generic versions of semaglutide.

What happened to the patent for semaglutide in India in 2026?

✓

Correct Choice

It expired in March 2026.

Which company is listed as a competitor launching generic semaglutide?

✓

Correct Choice

Sun Pharma.

What is the projected value of India's GLP-1 market by 2030?

✓

Correct Choice

Rs 5,000 crore.

Besides price, what factor does Novo Nordisk highlight to differentiate its products?

✓

Correct Choice

Clinical support and reliable manufacturing processes.

Ringoo Icon

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.

App StoreGoogle Play
Novo Nordisk adjusts strategy in India to compete with generic drugs | Ringoo